Q-omics provides the consensus-scored MIER3 profile across patient tissues and cancer cell-line models. MIER3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIER3 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, MIER3 RNA expression shows 21,368 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, COAD, and KIRP as cancer lineages where MIER3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIER3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIER3 survival associations across molecular data types. MIER3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIER3 RNA expression–survival associations across cancer types. High MIER3 expression shows unfavorable associations in KICH, UVM, KIRP and LIHC, but favorable associations in KIRC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIER3 RNA expression.
This table summarizes MIER3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MIER3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIER3 shows lower tumor expression in COAD, THCA and READ and higher tumor expression in LIHC, BRCA and CHOL. The COAD box plot shows higher MIER3 RNA expression in normal versus tumor tissue (log2 FC = −2.038, t-test p < 0.001).
This table shows molecular features associated with MIER3 in patient tissues and cancer cell lines. In patient samples, MIER3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, MIER3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
